{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T07:31:38Z","timestamp":1778657498248,"version":"3.51.4"},"reference-count":101,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"am","delay-in-days":355,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","award":["AI167933"],"award-info":[{"award-number":["AI167933"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","award":["AI176660"],"award-info":[{"award-number":["AI176660"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"NIDDK","doi-asserted-by":"publisher","award":["DK141106"],"award-info":[{"award-number":["DK141106"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"NIAMS","doi-asserted-by":"publisher","award":["AR070116"],"award-info":[{"award-number":["AR070116"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"NIAMS","doi-asserted-by":"publisher","award":["AR080219"],"award-info":[{"award-number":["AR080219"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"NIAMS","doi-asserted-by":"publisher","award":["AR077007"],"award-info":[{"award-number":["AR077007"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000862","name":"Doris Duke Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.iac.2025.06.005","type":"journal-article","created":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T04:00:32Z","timestamp":1755921632000},"page":"547-561","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Itch"],"prefix":"10.1016","volume":"45","author":[{"given":"Aaron M.","family":"Ver Heul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.iac.2025.06.005_bib1","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1016\/j.neuron.2022.03.031","article-title":"The translational revolution of itch","volume":"110","author":"Kim","year":"2022","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.iac.2025.06.005_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-immunol-101719-113805","article-title":"Immunosensation: neuroimmune cross talk in the skin","volume":"39","author":"Tamari","year":"2021","journal-title":"Annu Rev Immunol"},{"issue":"12","key":"10.1016\/j.iac.2025.06.005_bib3","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s00359-009-0482-z","article-title":"Nociceptors: a phylogenetic view","volume":"195","author":"Smith","year":"2009","journal-title":"J Comp Physiol A"},{"issue":"25","key":"10.1016\/j.iac.2025.06.005_bib4","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adj9173","article-title":"Harmonized cross-species cell atlases of trigeminal and dorsal root ganglia","volume":"10","author":"Bhuiyan","year":"2024","journal-title":"Sci Adv"},{"issue":"3","key":"10.1016\/j.iac.2025.06.005_bib5","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1152\/physrev.00017.2019","article-title":"Physiology and pathophysiology of itch","volume":"100","author":"Cevikbas","year":"2020","journal-title":"Physiol Rev"},{"issue":"4","key":"10.1016\/j.iac.2025.06.005_bib6","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.immuni.2024.03.008","article-title":"Sensory neurons: an integrated component of innate immunity","volume":"57","author":"Deng","year":"2024","journal-title":"Immunity"},{"issue":"6733","key":"10.1016\/j.iac.2025.06.005_bib7","doi-asserted-by":"crossref","DOI":"10.1126\/science.adn9390","article-title":"Scratching promotes allergic inflammation and host defense via neurogenic mast cell activation","volume":"387","author":"Liu","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.iac.2025.06.005_bib8","first-page":"808477","article-title":"The itch-scratch reflex generates protective immunity","author":"Radjavi","year":"2019","journal-title":"bioRxiv"},{"issue":"5","key":"10.1016\/j.iac.2025.06.005_bib9","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jid.2019.12.011","article-title":"The return of the mast cell: new roles in neuroimmune itch biology","volume":"140","author":"Wang","year":"2020","journal-title":"J Invest Dermatol"},{"issue":"5","key":"10.1016\/j.iac.2025.06.005_bib10","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.152559","article-title":"Dendritic cell immunoreceptor drives atopic dermatitis by modulating oxidized CaMKII-involved mast cell activation","volume":"7","author":"Luo","year":"2022","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/j.iac.2025.06.005_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2021.100519","article-title":"Targeting immunoglobulin E in atopic dermatitis: a review of the existing evidence","volume":"14","author":"Wollenberg","year":"2021","journal-title":"World Allergy Organ J"},{"issue":"1","key":"10.1016\/j.iac.2025.06.005_bib12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41572-022-00389-z","article-title":"Urticaria","volume":"8","author":"Kolkhir","year":"2022","journal-title":"Nat Rev Dis Primers"},{"issue":"22","key":"10.1016\/j.iac.2025.06.005_bib13","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJM199306033282204","article-title":"Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria","volume":"328","author":"Hide","year":"1993","journal-title":"New Engl J Medicine"},{"issue":"3","key":"10.1016\/j.iac.2025.06.005_bib14","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jaci.2017.10.035","article-title":"IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria","volume":"142","author":"Schmetzer","year":"2018","journal-title":"J Allergy Clin Immun"},{"issue":"1","key":"10.1016\/j.iac.2025.06.005_bib15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4168\/aair.2019.11.1.29","article-title":"Causal relationship between anti-TPO IgE and chronic urticaria by in vitro and in vivo tests","volume":"11","author":"S\u00e1nchez","year":"2018","journal-title":"Allergy Asthma Immunol Res"},{"issue":"7811","key":"10.1016\/j.iac.2025.06.005_bib16","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2311-z","article-title":"Sialylation of immunoglobulin E is a determinant of allergic pathogenicity","volume":"582","author":"Shade","year":"2020","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.iac.2025.06.005_bib17","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1016\/j.jaip.2023.02.006","article-title":"Most patients with autoimmune chronic spontaneous urticaria also have autoallergic urticaria, but not vice versa","volume":"11","author":"Xiang","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"10","key":"10.1016\/j.iac.2025.06.005_bib18","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"New Engl J Med"},{"issue":"10422","key":"10.1016\/j.iac.2025.06.005_bib19","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0140-6736(23)01684-7","article-title":"Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials","volume":"403","author":"Maurer","year":"2024","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.iac.2025.06.005_bib20","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jaip.2017.10.030","article-title":"Serum IgE as an immunological marker to predict response to omalizumab treatment in symptomatic chronic urticaria","volume":"6","author":"Straesser","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.iac.2025.06.005_bib21","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jaci.2016.07.047","article-title":"Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria","volume":"139","author":"Gericke","year":"2017","journal-title":"J Allergy Clin Immun"},{"issue":"10","key":"10.1016\/j.iac.2025.06.005_bib22","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1056\/NEJMoa2408792","article-title":"Remibrutinib in chronic spontaneous urticaria","volume":"392","author":"Metz","year":"2025","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.iac.2025.06.005_bib23","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.3390\/jcm11102807","article-title":"Bruton\u2019s kinase inhibitors for the treatment of immunological diseases: current status and perspectives","volume":"11","author":"Robak","year":"2022","journal-title":"J Clin Med"},{"issue":"8","key":"10.1016\/j.iac.2025.06.005_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202250359","article-title":"Mast cells in type 2 skin inflammation: maintenance and function","volume":"53","author":"Keith","year":"2023","journal-title":"Eur J Immunol"},{"issue":"11","key":"10.1016\/j.iac.2025.06.005_bib25","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1038\/s41590-019-0493-z","article-title":"House dust mites activate nociceptor-mast cell clusters to drive type 2 skin inflammation","volume":"20","author":"Serhan","year":"2019","journal-title":"Nat Immunol"},{"issue":"2","key":"10.1016\/j.iac.2025.06.005_bib26","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.cell.2020.12.033","article-title":"A basophil-neuronal axis promotes itch","volume":"184","author":"Wang","year":"2021","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.iac.2025.06.005_bib27","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.ajpath.2015.02.005","article-title":"Mast cells are dispensable in a genetic mouse model of chronic dermatitis","volume":"185","author":"Sulcova","year":"2015","journal-title":"Am J Pathol"},{"key":"10.1016\/j.iac.2025.06.005_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1292279","article-title":"Editorial: the fundamental biology of basophils in health and disease","volume":"14","author":"Pellefigues","year":"2023","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.iac.2025.06.005_bib31","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.jaci.2022.04.012","article-title":"KIT as a master regulator of the mast cell lineage","volume":"149","author":"Tsai","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.iac.2025.06.005_bib32","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/all.15585","article-title":"Anti-KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria","volume":"78","author":"Terhorst-Molawi","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.iac.2025.06.005_bib33","unstructured":"Jasper therapeutics presents clinical and preclinical briquilimab data at the american academy of allergy, Asthma, and Immunology (AAAAI) Annual Meeting. Available at: https:\/\/ir.jaspertherapeutics.com\/news-releases\/news-release-details\/jasper-therapeutics-presents-clinical-and-preclinical."},{"key":"10.1016\/j.iac.2025.06.005_bib34","unstructured":"Therapeutics C. Celldex Therapeutics presents positive data from prurigo nodularis phase 1b study demonstrating meaningful reduction in itch and skin clearing with single dose 3.0 mg\/kg barzolvolimab. Availble at: https:\/\/ir.celldex.com\/news-releases\/news-release-details\/celldex-therapeutics-presents-positive-data-prurigo-nodularis."},{"issue":"4","key":"10.1016\/j.iac.2025.06.005_bib35","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.immuni.2011.07.013","article-title":"Mast cell interleukin-2 production contributes to suppression of chronic allergic dermatitis","volume":"35","author":"Hershko","year":"2011","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.iac.2025.06.005_bib36","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.immuni.2023.12.012","article-title":"The MRGPR family of receptors in immunity","volume":"57","author":"Gour","year":"2024","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.iac.2025.06.005_bib37","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1001\/archderm.1964.01590280131024","article-title":"A pattern of pruritus due to chloroquine","volume":"89","author":"Ekpechi","year":"1964","journal-title":"Arch Dermatol"},{"issue":"7","key":"10.1016\/j.iac.2025.06.005_bib38","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.cell.2009.11.034","article-title":"Sensory neuron-specific GPCR Mrgprs are itch receptors mediating chloroquine-induced pruritus","volume":"139","author":"Liu","year":"2024","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.iac.2025.06.005_bib39","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1248\/bpb.b24-00522","article-title":"MrgprA3+ primary sensory neurons mediate acute allergic itch responses in atopic dermatitis model mice","volume":"47","author":"Fujii","year":"2024","journal-title":"Biol Pharm Bull"},{"issue":"21","key":"10.1016\/j.iac.2025.06.005_bib40","doi-asserted-by":"crossref","first-page":"10525","DOI":"10.1073\/pnas.1903316116","article-title":"MRGPRX4 is a G protein-coupled receptor activated by bile acids that may contribute to cholestatic pruritus","volume":"116","author":"Meixiong","year":"2019","journal-title":"Proc Natl Acad Sci"},{"issue":"746","key":"10.1016\/j.iac.2025.06.005_bib41","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adk8198","article-title":"MRGPRX4 mediates phospho-drug\u2013associated pruritus in a humanized mouse model","volume":"16","author":"Chien","year":"2024","journal-title":"Sci Transl Med"},{"issue":"11","key":"10.1016\/j.iac.2025.06.005_bib42","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1111\/bcp.15845","article-title":"MRGPRX2, drug pseudoallergies, inflammatory diseases, mechanisms and distinguishing MRGPRX2- and IgE\/Fc\u03b5RI-mediated events","volume":"89","author":"Baldo","year":"2023","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.iac.2025.06.005_bib43","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.immuni.2019.03.013","article-title":"Activation of mast-cell-expressed mas-related G-protein-coupled receptors drives non-histaminergic itch","volume":"50","author":"Meixiong","year":"2021","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.iac.2025.06.005_bib44","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.clinthera.2020.01.025","article-title":"Effects of stress on itch","volume":"42","author":"Golpanian","year":"2020","journal-title":"Clin Ther"},{"issue":"3","key":"10.1016\/j.iac.2025.06.005_bib45","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.bbi.2004.08.005","article-title":"Stress exposure modulates peptidergic innervation and degranulates mast cells in murine skin","volume":"19","author":"Peters","year":"2005","journal-title":"Brain Behav Immun"},{"issue":"2","key":"10.1016\/j.iac.2025.06.005_bib46","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.cell.2013.08.057","article-title":"The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch","volume":"155","author":"Wilson","year":"2013","journal-title":"Cell"},{"issue":"47","key":"10.1016\/j.iac.2025.06.005_bib47","doi-asserted-by":"crossref","first-page":"E7572","DOI":"10.1073\/pnas.1606608113","article-title":"IL-33\/ST2 signaling excites sensory neurons and mediates itch response in a mouse model of poison ivy contact allergy","volume":"113","author":"Liu","year":"2016","journal-title":"Proc National Acad Sci"},{"issue":"4","key":"10.1016\/j.iac.2025.06.005_bib48","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.jaci.2021.09.014","article-title":"IL-33 signaling in sensory neurons promotes dry skin itch","volume":"149","author":"Trier","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2025.06.005_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2023.1258823","article-title":"Type 2 cytokines sensitize human sensory neurons to itch-associated stimuli","volume":"16","author":"Mack","year":"2023","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.iac.2025.06.005_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.772941","article-title":"Cutaneous neuroimmune interactions of TSLP and TRPV4 play pivotal roles in dry skin-induced pruritus","volume":"12","author":"Lee","year":"2021","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.iac.2025.06.005_bib51","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.jaci.2023.08.038","article-title":"IL-33 potentiates histaminergic itch","volume":"153","author":"Trier","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2025.06.005_bib52","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jaad.2018.11.059","article-title":"Tezepelumab, an anti\u2013thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: a randomized phase 2a clinical trial","volume":"80","author":"Simpson","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"515","key":"10.1016\/j.iac.2025.06.005_bib53","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax2945","article-title":"Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis","volume":"11","author":"Chen","year":"2019","journal-title":"Sci Transl Med"},{"issue":"6","key":"10.1016\/j.iac.2025.06.005_bib54","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.jaci.2025.01.045","article-title":"Tezepelumab for the treatment of chronic spontaneous urticaria: results of the phase 2b INCEPTION study","volume":"155","author":"McLaren","year":"2025","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2025.06.005_bib55","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jaci.2013.10.048","article-title":"A sensory neuron\u2013expressed IL-31 receptor mediates T helper cell\u2013dependent itch: involvement of TRPV1 and TRPA1","volume":"133","author":"Cevikbas","year":"2014","journal-title":"J Allergy Clin Immun"},{"issue":"2","key":"10.1016\/j.iac.2025.06.005_bib56","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jaci.2016.02.020","article-title":"The pruritus- and TH2-associated cytokine IL-31 promotes growth of sensory nerves","volume":"138","author":"Feld","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.iac.2025.06.005_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113433","article-title":"Sensory neuronal STAT3 is critical for IL-31 receptor expression and inflammatory itch","volume":"42","author":"Takahashi","year":"2023","journal-title":"Cell Rep"},{"key":"10.1016\/j.iac.2025.06.005_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.638325","article-title":"Interleukin-31 as a clinical target for pruritus treatment","volume":"8","author":"Kabashima","year":"2021","journal-title":"Front Med"},{"issue":"17","key":"10.1016\/j.iac.2025.06.005_bib59","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1056\/NEJMoa2301333","article-title":"Phase 3 trial of nemolizumab in patients with prurigo nodularis","volume":"389","author":"Kwatra","year":"2023","journal-title":"N Engl J Med"},{"issue":"10451","key":"10.1016\/j.iac.2025.06.005_bib60","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0140-6736(24)01203-0","article-title":"Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials","volume":"404","author":"Silverberg","year":"2024","journal-title":"Lancet"},{"issue":"88","key":"10.1016\/j.iac.2025.06.005_bib61","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abi6887","article-title":"IL-31\u2013dependent neurogenic inflammation restrains cutaneous type 2 immune response in allergic dermatitis","volume":"8","author":"Fassett","year":"2023","journal-title":"Sci Immunol"},{"issue":"2","key":"10.1016\/j.iac.2025.06.005_bib62","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.alit.2025.02.001","article-title":"Neuroimmune mechanisms of type 2 inflammation in the skin and lung","volume":"74","author":"Tamari","year":"2025","journal-title":"Allergol Int"},{"issue":"619","key":"10.1016\/j.iac.2025.06.005_bib63","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abe3037","article-title":"Oncostatin M can sensitize sensory neurons in inflammatory pruritus","volume":"13","author":"Tseng","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.iac.2025.06.005_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101826","article-title":"Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor \u03b2 antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study","volume":"57","author":"Sofen","year":"2023","journal-title":"eClinicalMedicine"},{"issue":"1","key":"10.1016\/j.iac.2025.06.005_bib65","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","article-title":"Sensory neurons Co-opt classical immune signaling pathways to mediate chronic itch","volume":"171","author":"Oetjen","year":"2017","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.iac.2025.06.005_bib66","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1111\/exd.14034","article-title":"Interleukin-4 and interleukin-13 evoke scratching behaviour in mice","volume":"28","author":"Campion","year":"2019","journal-title":"Exp Dermatol"},{"issue":"3","key":"10.1016\/j.iac.2025.06.005_bib67","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.jaci.2022.01.028","article-title":"Mechanistic insights into the antipruritic effects of lebrikizumab, an anti\u2013IL-13 mAb","volume":"150","author":"Miron","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"24","key":"10.1016\/j.iac.2025.06.005_bib68","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"New Engl J Med"},{"issue":"3","key":"10.1016\/j.iac.2025.06.005_bib69","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2020","journal-title":"Brit J Dermatol"},{"issue":"12","key":"10.1016\/j.iac.2025.06.005_bib70","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","article-title":"Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis","volume":"388","author":"Silverberg","year":"2023","journal-title":"New Engl J Med"},{"issue":"5","key":"10.1016\/j.iac.2025.06.005_bib71","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41591-023-02320-9","article-title":"Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials","volume":"29","author":"Yosipovitch","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.iac.2025.06.005_bib72","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jaci.2024.01.028","article-title":"Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): two randomized, double-blind, placebo-controlled, phase 3 trials","volume":"154","author":"Maurer","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"10.1016\/j.iac.2025.06.005_bib73","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamadermatol.2023.2428","article-title":"Evaluation of dupilumab in patients with bullous pemphigoid","volume":"159","author":"Zhao","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.iac.2025.06.005_bib74","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1097\/itx.0000000000000064","article-title":"Therapeutics in chronic pruritus of unknown origin","volume":"8","author":"Ju","year":"2023","journal-title":"Itch"},{"issue":"3","key":"10.1016\/j.iac.2025.06.005_bib75","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1080\/09546634.2021.1880542","article-title":"Treatment of patients with chronic pruritus of unknown origin with dupilumab","volume":"33","author":"Jeon","year":"2022","journal-title":"J Dermatol Treat"},{"issue":"10","key":"10.1016\/j.iac.2025.06.005_bib76","first-page":"CD011224","article-title":"Leukotriene receptor antagonists for eczema","volume":"2018","author":"Ferguson","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.iac.2025.06.005_bib77","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jaad.2017.12.077","article-title":"An assessment of the use of antihistamines in the management of atopic dermatitis","volume":"79","author":"He","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"21","key":"10.1016\/j.iac.2025.06.005_bib78","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1016\/j.cell.2022.09.023","article-title":"The JAK-STAT pathway at 30: much learned, much more to do","volume":"185","author":"Philips","year":"2022","journal-title":"Cell"},{"issue":"10290","key":"10.1016\/j.iac.2025.06.005_bib79","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","article-title":"Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"issue":"10246","key":"10.1016\/j.iac.2025.06.005_bib80","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","article-title":"Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"396","author":"Simpson","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.iac.2025.06.005_bib81","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/jamadermatol.2022.0455","article-title":"Systemic immunomodulatory treatments for atopic dermatitis","volume":"158","author":"Drucker","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"12","key":"10.1016\/j.iac.2025.06.005_bib82","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","article-title":"Abrocitinib versus placebo or dupilumab for atopic dermatitis","volume":"384","author":"Bieber","year":"2021","journal-title":"New Engl J Med"},{"issue":"7","key":"10.1016\/j.iac.2025.06.005_bib83","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1001\/jamadermatol.2024.1464","article-title":"Efficacy and safety of abrocitinib in prurigo nodularis and chronic pruritus of unknown origin","volume":"160","author":"Kwatra","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"11","key":"10.1016\/j.iac.2025.06.005_bib84","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.3390\/ph17111499","article-title":"Therapies for chronic spontaneous urticaria: present and future developments","volume":"17","author":"Asero","year":"2024","journal-title":"Pharmaceuticals"},{"issue":"12","key":"10.1016\/j.iac.2025.06.005_bib85","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1001\/jamadermatol.2019.2804","article-title":"Treatment of refractory chronic pruritus of unknown origin with tofacitinib in patients with rheumatoid arthritis","volume":"155","author":"Wang","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"8033","key":"10.1016\/j.iac.2025.06.005_bib86","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41586-024-07869-0","article-title":"A \u03b3\u03b4 T cell\u2013IL-3 axis controls allergic responses through sensory neurons","volume":"634","author":"Flayer","year":"2024","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.iac.2025.06.005_bib87","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jaci.2016.12.960","article-title":"Janus-kinase inhibitors display broad anti-itch properties - a possible link via the TRPV1 receptor","volume":"140","author":"Fukuyama","year":"2017","journal-title":"J Allergy Clin Immun"},{"key":"10.1016\/j.iac.2025.06.005_bib88","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.78301","article-title":"Tyrosine phosphorylation tunes chemical and thermal sensitivity of TRPV2 ion channel","volume":"11","author":"Mo","year":"2022","journal-title":"eLife"},{"key":"10.1016\/j.iac.2025.06.005_bib89","unstructured":"Incyte announces results from SCRATCH-AD trial demonstrating substantial and rapid itch reduction in patients with mild-moderate atopic dermatitis treated with opzelura\u00ae (ruxolitinib) cream. Available at: https:\/\/investor.incyte.com\/news-releases\/news-release-details\/incyte-announces-results-scratch-ad-trial-demonstrating."},{"issue":"6462","key":"10.1016\/j.iac.2025.06.005_bib90","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaw9997","article-title":"Axonal transport: driving synaptic function","volume":"366","author":"Guedes-Dias","year":"2019","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.iac.2025.06.005_bib91","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/j.pain.0000000000001141","article-title":"Itch and neuropathic itch","volume":"159","author":"Hachisuka","year":"2018","journal-title":"Pain"},{"issue":"1","key":"10.1016\/j.iac.2025.06.005_bib92","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-29965-8","article-title":"MRGPRX2-mediated mast cell response to drugs used in perioperative procedures and anaesthesia","volume":"8","author":"Navin\u00e9s-Ferrer","year":"2018","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.iac.2025.06.005_bib93","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.neuron.2018.08.044","article-title":"Kappa opioid receptor distribution and function in primary afferents","volume":"99","author":"Snyder","year":"2018","journal-title":"Neuron"},{"issue":"7","key":"10.1016\/j.iac.2025.06.005_bib94","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.3390\/jcm12072474","article-title":"Endogenous opioid imbalance as a potential factor involved in the pathogenesis of chronic kidney disease-associated pruritus in dialysis patients","volume":"12","author":"Wala-Zieli\u0144ska","year":"2023","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.iac.2025.06.005_bib95","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1912770","article-title":"A phase 3 trial of difelikefalin in hemodialysis patients with pruritus","volume":"382","author":"Fishbane","year":"2020","journal-title":"New Engl J Med"},{"issue":"4","key":"10.1016\/j.iac.2025.06.005_bib96","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/ndt\/gfp588","article-title":"Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study","volume":"25","author":"Kumagai","year":"2010","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.iac.2025.06.005_bib97","doi-asserted-by":"crossref","DOI":"10.1097\/itx.0000000000000072","article-title":"Kappa opioid agonists in the treatment of itch: just scratching the surface?","volume":"8","author":"Beck","year":"2023","journal-title":"Itch"},{"issue":"4","key":"10.1016\/j.iac.2025.06.005_bib98","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jaci.2023.06.022","article-title":"Difelikefalin suppresses itch and reduces scratching independent of inflammation in a murine model of atopic dermatitis","volume":"152","author":"Tamari","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2025.06.005_bib99","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.jaci.2023.06.023","article-title":"Oral difelikefalin reduces moderate-to-severe pruritus and expression of pruritic and inflammatory biomarkers in subjects with atopic dermatitis","volume":"52","author":"Guttman-Yassky","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2025.06.005_bib100","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jaad.2023.03.051","article-title":"A phase 2 study of oral difelikefalin in subjects with chronic kidney disease and moderate-to-severe pruritus","volume":"89","author":"Yosipovitch","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.iac.2025.06.005_bib101","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa2210699","article-title":"Phase 2 trial of difelikefalin in notalgia paresthetica","volume":"388","author":"Kim","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.iac.2025.06.005_bib102","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jaad.2005.12.010","article-title":"Butorphanol for treatment of intractable pruritus","volume":"54","author":"Dawn","year":"2006","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.iac.2025.06.005_bib103","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1093\/jleuko\/qiae230","article-title":"The peripheral neuroimmune system","volume":"116","author":"Song","year":"2024","journal-title":"J Leukoc Biol"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856125000499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856125000499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T01:41:48Z","timestamp":1761183708000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856125000499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":101,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0889856125000499"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2025.06.005","relation":{},"ISSN":["0889-8561"],"issn-type":[{"value":"0889-8561","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Itch","name":"articletitle","label":"Article Title"},{"value":"Immunology and Allergy Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iac.2025.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}